Amplo Biotechnology, founded in Pompano Beach, Florida, is dedicated to developing Adeno-Associated Viral (AAV) therapies targeting neuromuscular junction diseases, with a primary focus on congenital myasthenic syndromes. Their lead program, AAV-Dok7, aims to address severe health issues such as paralysis and breathing difficulties by leveraging the research of Professor Yuji Yamanashi from the University of Tokyo. Amplo's mission is to create potentially curative treatments that significantly improve patients' quality of life.
Key figures at Amplo Biotechnology include CEO Patricio Sepulveda, President Al Hawkins, and Executive Chair Dan Bradbury. The company collaborates globally with top-tier scientists and institutions to advance their innovative therapies. Notable achievements include the development of AMP-101 and AAV-Dok7 gene therapy programs. Amplo's impact lies in its potential to revolutionize treatment for neuromuscular diseases, offering hope to patients who currently have limited therapeutic options.
